Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 3
1990 2
1991 1
1992 5
1993 2
1994 1
1995 5
1996 4
1997 7
1998 2
1999 11
2000 5
2001 4
2002 11
2003 13
2004 17
2005 20
2006 21
2007 26
2008 28
2009 35
2010 37
2011 53
2012 54
2013 73
2014 85
2015 86
2016 100
2017 78
2018 78
2019 88
2020 117
2021 113
2022 91
2023 87
2024 38

Text availability

Article attribute

Article type

Publication date

Search Results

1,183 results

Results by year

Filters applied: . Clear all
Page 1
AGE-RELATED MACULAR DEGENERATION.
Gheorghe A, Mahdi L, Musat O. Gheorghe A, et al. Rom J Ophthalmol. 2015 Apr-Jun;59(2):74-7. Rom J Ophthalmol. 2015. PMID: 26978865 Free PMC article. Review.
It is characterized by the appearance of drusen in the macula, accompanied by choroidal neovascularization (CNV) or geographic atrophy....
It is characterized by the appearance of drusen in the macula, accompanied by choroidal neovascularization (CNV) or geographic atr …
C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.
Jaffe GJ, Westby K, Csaky KG, Monés J, Pearlman JA, Patel SS, Joondeph BC, Randolph J, Masonson H, Rezaei KA. Jaffe GJ, et al. Ophthalmology. 2021 Apr;128(4):576-586. doi: 10.1016/j.ophtha.2020.08.027. Epub 2020 Sep 1. Ophthalmology. 2021. PMID: 32882310 Free article. Clinical Trial.
The safety and efficacy of avacincaptad pegol (Zimura, IVERIC bio Inc, New York, NY), a C5 inhibitor, were assessed in participants with geographic atrophy (GA) secondary to AMD (GATHER1 Study). DESIGN: International, prospective, randomized, double-masked, sham-con …
The safety and efficacy of avacincaptad pegol (Zimura, IVERIC bio Inc, New York, NY), a C5 inhibitor, were assessed in participants with …
Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.
Liao DS, Grossi FV, El Mehdi D, Gerber MR, Brown DM, Heier JS, Wykoff CC, Singerman LJ, Abraham P, Grassmann F, Nuernberg P, Weber BHF, Deschatelets P, Kim RY, Chung CY, Ribeiro RM, Hamdani M, Rosenfeld PJ, Boyer DS, Slakter JS, Francois CG. Liao DS, et al. Ophthalmology. 2020 Feb;127(2):186-195. doi: 10.1016/j.ophtha.2019.07.011. Epub 2019 Jul 16. Ophthalmology. 2020. PMID: 31474439 Free article. Clinical Trial.
PURPOSE: Geographic atrophy (GA), a late stage of age-related macular degeneration (AMD), is a major cause of blindness. ...
PURPOSE: Geographic atrophy (GA), a late stage of age-related macular degeneration (AMD), is a major cause of blindness. ...
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
Heier JS, Lad EM, Holz FG, Rosenfeld PJ, Guymer RH, Boyer D, Grossi F, Baumal CR, Korobelnik JF, Slakter JS, Waheed NK, Metlapally R, Pearce I, Steinle N, Francone AA, Hu A, Lally DR, Deschatelets P, Francois C, Bliss C, Staurenghi G, Monés J, Singh RP, Ribeiro R, Wykoff CC; OAKS and DERBY study investigators. Heier JS, et al. Lancet. 2023 Oct 21;402(10411):1434-1448. doi: 10.1016/S0140-6736(23)01520-9. Lancet. 2023. PMID: 37865470 Clinical Trial.
BACKGROUND: Geographic atrophy is a leading cause of progressive, irreversible vision loss. ...INTERPRETATION: Pegcetacoplan, the first treatment approved by the US Food and Drug Administration for geographic atrophy, slowed geographic atroph …
BACKGROUND: Geographic atrophy is a leading cause of progressive, irreversible vision loss. ...INTERPRETATION: Pegcetacoplan, …
Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement system.
Bakri SJ, Bektas M, Sharp D, Luo R, Sarda SP, Khan S. Bakri SJ, et al. J Manag Care Spec Pharm. 2023 May;29(5-a Suppl):S2-S11. doi: 10.18553/jmcp.2023.29.5-a.s2. J Manag Care Spec Pharm. 2023. PMID: 37125931 Free PMC article.
Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD), characterized by atrophic lesions that first start in the outer retina and progressively expand to cover the macula and the fovea, the center of the macula, leading to irreversibl …
Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD), characterized by atrophic lesions that …
Age-Related Macular Degeneration: Epidemiology and Clinical Aspects.
Keenan TDL, Cukras CA, Chew EY. Keenan TDL, et al. Adv Exp Med Biol. 2021;1256:1-31. doi: 10.1007/978-3-030-66014-7_1. Adv Exp Med Biol. 2021. PMID: 33847996
Late AMD is divided into neovascular and atrophic forms, though these can coexist. The defining lesions are macular neovascularization and geographic atrophy, respectively. At this stage, visual symptoms are often severe and irreversible, and can comprise profoundly …
Late AMD is divided into neovascular and atrophic forms, though these can coexist. The defining lesions are macular neovascularization and …
THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGET.
Boyer DS, Schmidt-Erfurth U, van Lookeren Campagne M, Henry EC, Brittain C. Boyer DS, et al. Retina. 2017 May;37(5):819-835. doi: 10.1097/IAE.0000000000001392. Retina. 2017. PMID: 27902638 Free PMC article. Review.
PURPOSE: Geographic atrophy (GA) is an advanced, vision-threatening form of age-related macular degeneration (AMD) affecting approximately five million individuals worldwide. ...
PURPOSE: Geographic atrophy (GA) is an advanced, vision-threatening form of age-related macular degeneration (AMD) affecting a …
COMPLEMENT INHIBITION FOR GEOGRAPHIC ATROPHY: Review of Salient Functional Outcomes and Perspective.
Spaide RF, Vavvas DG. Spaide RF, et al. Retina. 2023 Jul 1;43(7):1064-1069. doi: 10.1097/IAE.0000000000003796. Retina. 2023. PMID: 36996460 Clinical Trial.
PURPOSE: To evaluate available rationale and outcomes of randomized trial results for complement inhibition for geographic atrophy. METHODS: Data from recently completed randomized trials of complement inhibition, particularly for pegcetacoplan and avacincaptad pego …
PURPOSE: To evaluate available rationale and outcomes of randomized trial results for complement inhibition for geographic atrophy …
Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial.
Patel SS, Lally DR, Hsu J, Wykoff CC, Eichenbaum D, Heier JS, Jaffe GJ, Westby K, Desai D, Zhu L, Khanani AM. Patel SS, et al. Eye (Lond). 2023 Dec;37(17):3551-3557. doi: 10.1038/s41433-023-02497-w. Epub 2023 Mar 24. Eye (Lond). 2023. PMID: 36964259 Free PMC article. Clinical Trial.
BACKGROUND/OBJECTIVES: To assess the safety and efficacy of avacincaptad pegol (ACP), a C5 inhibitor, for geographic atrophy (GA) secondary to age-related macular degeneration (AMD) over an 18-month treatment course. ...
BACKGROUND/OBJECTIVES: To assess the safety and efficacy of avacincaptad pegol (ACP), a C5 inhibitor, for geographic atrophy ( …
Identifying geographic atrophy.
Clevenger L, Rachitskaya A. Clevenger L, et al. Curr Opin Ophthalmol. 2023 May 1;34(3):195-202. doi: 10.1097/ICU.0000000000000952. Epub 2023 Mar 17. Curr Opin Ophthalmol. 2023. PMID: 36943458 Review.
PURPOSE OF REVIEW: Age-related macular degeneration (AMD) is one of the leading causes of blindness and can progress to geographic atrophy (GA) in late stages of disease. This review article highlights recent literature which assists in the accurate and timely ident …
PURPOSE OF REVIEW: Age-related macular degeneration (AMD) is one of the leading causes of blindness and can progress to geographic …
1,183 results